Keros Therapeutics, Inc. (KROS) Stock Price & Analysis
Keros Therapeutics, Inc. (KROS) rose 0.70% to USD 10.07 as of June 10, 2026 at 01:58 UTC, according to Nexqual real-time market data.
KROS last closed at USD 10; the session ranged USD 9.9–10.34 on volume of 194,167 shares. Market capitalization is $199.30M, with a 52-week range of USD 9.79–22.55 (NGM). Source: Nexqual, June 10, 2026 at 01:58 UTC.
Key Statistics (as of June 10, 2026 at 01:58 UTC)
| Price | USD 10.07 |
|---|---|
| Change | ▲ 0.70% (up) |
| Previous Close | USD 10 |
| Open | USD 10.1 |
| Day Range | USD 9.9 – 10.34 |
| 52-Week Range | USD 9.79 – 22.55 |
| Volume | 194,167 shares |
| Market Cap | $199.30M |
| Exchange | NGM |
Technical Analysis (KROS)
Nexqual's technical model rates KROS "SELL" based on 1 bullish and 5 bearish signals across 124 daily candles, as of June 10, 2026 at 01:58 UTC.
| Overall Signal | SELL |
|---|---|
| RSI (14) | 37.89 (neutral) |
| vs SMA50 | Below (USD 11.3) |
| MACD | -0.32 (negative) |
Analyst Ratings (KROS)
Wall Street analysts rate KROS "Buy" based on 6 analysts, with a mean price target of USD 21.83 (range USD 16–30), per Nexqual as of June 10, 2026 at 01:58 UTC.
| Consensus Rating | Buy |
|---|---|
| Analyst Count | 6 |
| Mean Target | USD 21.83 |
| High Target | USD 30 |
| Low Target | USD 16 |
| Buy / Hold / Sell | 3 / 4 / 0 |
Earnings (KROS)
| Next Earnings Date | 2026-08-05 |
|---|---|
| EPS Estimate | USD -1.24 |
| Revenue Estimate | $706,250 |
Recent Earnings History
| Quarter | Actual vs Estimate |
|---|---|
| 2026-03-31 | USD -1.21 vs est -0.92 ▼ miss |
| 2025-12-31 | USD -0.86 vs est -0.45 ▼ miss |
| 2025-09-30 | USD -0.18 vs est -0.92 ▲ beat |
| 2025-06-30 | USD -0.76 vs est -1.13 ▲ beat |
Source: Nexqual, June 10, 2026 at 01:58 UTC.
Financials & Fundamentals (KROS)
| Total Revenue | $33.18M |
|---|---|
| Revenue Growth (YoY) | -99.80% |
| Gross Margin | -184.89% |
| Operating Margin | -7050.95% |
| Profit Margin | -256.60% |
| ROE | -16.79% |
| Debt / Equity | 5.71 |
| Current Ratio | 22.62 |
| Total Cash | $281.50M |
| Total Debt | $16.31M |
| Free Cash Flow | $-37.69M |
Source: Nexqual, June 10, 2026 at 01:58 UTC.
Financial Health Score (KROS)
Nexqual rates Keros Therapeutics, Inc.'s overall financial health "Weak" across five dimensions, as of June 10, 2026 at 01:58 UTC.
| Growth | Mixed — No data |
|---|---|
| Profitability | Critical — Heavily loss-making — early-stage company |
| Balance Sheet | Strong — $281M cash vs $16M debt, net cash position |
| Cash Flow | Weak — FCF negative: -$38M, burning cash |
| Efficiency | Critical — ROE -17%, ROA -12.2% |
Ownership (KROS)
| Insider Ownership | +3.68% |
|---|---|
| Institutional Ownership | +96.14% |
| Shares Outstanding | 19.79M |
| Float | 17.83M |
| Short % of Float | +8.77% |
Source: Nexqual, June 10, 2026 at 01:58 UTC.
Leadership (KROS)
Keros Therapeutics, Inc. is led by Jasbir S. Seehra (age 69), President, CEO & Director, per Nexqual as of June 10, 2026 at 01:58 UTC.
| President, CEO & Director | Jasbir S. Seehra (age 69) |
|---|---|
| Chief Financial Officer | Keith C. Regnante (age 55) |
| Chief Scientific Officer | Lorena Lerner (age 53) |
Major Backers & Investors (KROS)
Notable institutional backers of Keros Therapeutics, Inc. include Nantahala Capital Management, LLC, Federated Hermes, Inc., Orbimed Advisors LLC., according to Nexqual as of June 10, 2026 at 01:58 UTC.
Active Investors
| Investor | Stake |
|---|---|
| Nantahala Capital Management, LLC | 6.87% |
| Federated Hermes, Inc. | 5.32% |
| Orbimed Advisors LLC. | 3.84% |
| Qube Research & Technologies Ltd | 3.66% |
| Jacobs Levy Equity Management, Inc. | 3.57% |
| Madison Avenue Partners, LP | 3.17% |
| Fidelity | 1.45% |
Index Funds (Passive)
| Fund | Stake |
|---|---|
| BlackRock | 16.9% |
| Vanguard Group | 13.69% |
| Geode Capital | 3.44% |
Source: Nexqual, June 10, 2026 at 01:58 UTC.
From Keros Therapeutics, Inc.'s Latest SEC 10-K Filing (filed 2026-03-04)
Key Strengths & Strategy (as disclosed to the SEC)
- We intend to also opportunistically evaluate strategic collaborations to maximize the potential commercial value of our product candidates and discovery programs. • Leverage our proprietary discovery approach and knowledge base to develop new therapeutics .
- Phase 3 Clinical Trial Design Our Preclinical Pipeline Our Proprietary Discovery Approach We believe, based on our previous experience with ActRII ligand traps using endogenous and wild-type sequences, that observations in preclinical rodent models have the potential to translate to humans in the clinic.
- We have developed a proprietary library of ActRII ligand traps by combining sequences from ActRIIA and ActRIIB.
Partnerships
- In December 2024, we entered into an exclusive license agreement with Takeda Pharmaceuticals U.S.A., Inc., or Takeda, to further develop, manufacture and commercialize elritercept worldwide outside of mainland China, Hong Kong and Macau, which became effective on January 16, 2025.
- The dosing of the first patient triggered a $10 million milestone payment to us under the license agreement with Takeda.
Source: SEC EDGAR 10-K, official filing. Curated by Nexqual.
Peers & Related Stocks
| Symbol | Name | Price | Change |
|---|---|---|---|
| ZNTL | Zentalis Pharmaceuticals, Inc. | USD 3.58 | ▼ 2.19% |
| KYMR | Kymera Therapeutics, Inc. | USD 76.91 | ▲ 3.75% |
| ORIC | Oric Pharmaceuticals, Inc. | USD 8 | ▲ 6.67% |
| INBX | Inhibrx Biosciences, Inc. | USD 89.1 | ▲ 2.4% |
| PCVX | Vaxcyte, Inc. | USD 46.88 | ▼ 1.01% |
Data source: Nexqual — real-time market data, technical indicators, analyst consensus, earnings, SEC EDGAR filings. Last updated: June 10, 2026 at 01:58 UTC. This page is informational and not investment advice.